Gilead Sciences, Inc. (GILD)
| Market Cap | 140.93B |
| Revenue (ttm) | 28.86B |
| Net Income (ttm) | 6.31B |
| Shares Out | 1.24B |
| EPS (ttm) | 5.01 |
| PE Ratio | 22.67 |
| Forward PE | 13.52 |
| Dividend | $3.16 (2.78%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 9,090,384 |
| Open | 115.67 |
| Previous Close | 112.69 |
| Day's Range | 112.41 - 117.00 |
| 52-Week Range | 84.17 - 121.83 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 116.36 (+2.45%) |
| Earnings Date | Nov 5, 2025 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for GILD stock is "Buy." The 12-month stock price target is $116.36, which is an increase of 2.45% from the latest price.
News
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Dividend Shields: Top 5 Income Stocks
Market optimism has waned as investors weighed mixed data, Fed guidance, and sector-specific risks after the S&P 500 hit eight record highs in September. Strong GDP and jobs data have tempered rate cu...
Hanmi's Oral Delivery Platform Compound Licensed to Gilead
Hanmi and HHP will grant Gilead an exclusive license to Encequidar and provide access to drug supply. SEOUL, South Korea , Sept.
Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen
Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.
Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has committed more than $6.5 million in grant funding toward strengthening science, technology, engin...
Gilead Sciences: Yeztugo And Trodelvy Make This A Buy Once More
Gilead Sciences is upgraded to 'Buy' as YEZTUGO's FDA approval strengthens its dominant HIV franchise and long-term outlook. GILD's valuation remains attractive, with a P/E of 14.74 and significant up...
Fangzhou Wins Gilead ‘Award of Excellence' for AI-Driven Chronic Disease Management
SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, received the “Excellence Award” at Gilead Scie...
Gilead Sciences, Inc. (GILD) Presents At Baird Global Healthcare Conference 2025 Transcript
Gilead Sciences, Inc. (NASDAQ:GILD) Baird Global Healthcare Conference 2025 September 10, 2025 11:25 AM EDT Company Participants Cindy Perettie - Executive Vice President of Kite Conference Call Part...
Gilead Sciences, Inc. (GILD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Daniel O'Day - Chairman & CEO Johanna Mercier - Chief C...
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief...
US plans to bring Gilead HIV drug to market in high-burden HIV countries
The U.S. State Department announced a plan on Thursday to bring Gilead Sciences Inc's drug lenacapavir to market "at cost" in high-burden HIV countries in an effort to reach 2 million people over thre...
Gilead Sciences, Inc. (GILD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Gilead Sciences, Inc. (NASDAQ:GILD) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 11:00 AM EDT Company Participants Andrew Dickinson - Chief Financial Officer Conference Call P...
Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of Choose U™, a new campaign that spotlights the multifaceted experiences of people living with HI...
Gilead Sciences, Inc. (GILD) Presents At Cantor Global Healthcare Conference 2025 Transcript
Gilead Sciences, Inc. (NASDAQ:GILD) Cantor Global Healthcare Conference 2025 September 3, 2025 11:30 AM EDT Company Participants Dietmar Berger - Chief Medical Officer Conference Call Participants Ca...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Gilead starts building manufacturing hub under $32 billion planned US investments
Gilead Sciences said on Wednesday it has started work on a new pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, as part of its planned $32 billion inves...
Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences (Nasdaq: GILD) today celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTD...
Gilead Sciences: HIV Leadership Outshines Decline In COVID-19 Drug Sales
Despite retail investors' cautious attitude toward Gilead Sciences, it once again beat analysts' expectations by a wide margin. In my estimation, Gilead's main star remains Biktarvy, which leaves comp...
EU approves Gilead's new injection for preventing HIV
The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV infection, the company said on Tuesday.
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company's...
Gilead unit to acquire cell therapy developer Interius for $350 million
Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for $350 million in cash to advance CAR T-cell cancer therapies that are deliver...
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
CVS Health Inc. CVS said it will not add Gilead Sciences Inc.'s GILD new HIV prevention drug Yeztugo to its commercial plans.
Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
SANTA MONICA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.
From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave
Gilead Sciences remains a long-term Buy due to solid quarterly results, raised guidance, and continued strength in its HIV portfolio, especially Biktarvy. The recent launch of Yeztugo and a robust HIV...
Exclusive: CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists
CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medic...